Program
TUESDAY, MARCH 11
- Welcome and Keynote Lecture
- Plenary Session 1: Functional and Genomic Precision Medicine in Blood Cancers
WEDNESDAY, MARCH 12
- Plenary Session 2: Functional and Genomic Precision Medicine in Solid Tumors
- Plenary Session 3: Ex vivo patient-derived Models to Identify Biomarkers of Response
- Plenary Session 4: Vertebrate Models for Modeling Disease and Guiding Therapy
- Plenary Session 5: Challenges of Intra-Tumor and Intra-Patient Heterogeneity for Precision Medicine
THURSDAY, MARCH 13
- Plenary Session 6: New Omics for Precision Medicine
- Plenary Session 7: Machine Learning to Integrate Multiple Data Layers
- Plenary Session 8: Immunotherapy-predictive Biomarkers
- Plenary Session 9: Clinical Trial Design for Optimal Implementation of Precision Medicine
- Closing Remarks
WELCOME AND OPENING Keynote
5-6:30 p.m. | CME Eligible
- 5 p.m. | Welcome and Introduction of Keynote Speaker
Anthony G. Letai, Dana-Farber Cancer Institute, Boston, Massachusetts - 5:05 p.m. | Keynote
Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, New York - 5:45 p.m. | Introduction of Keynote Speaker
Elaine R. Mardis, The Institute for Genomic Medicine at Nationwide Children’s Hospital, Columbus, Ohio - 5:50 p.m. | Keynote
Jeffrey W. Tyner, OHSU Knight Cancer Institute, Portland, Oregon
BREAK
6:30-6:45 p.m.
Plenary Session 1: Functional and Genomic Precision Medicine in Blood Cancers
6:45-8:20 p.m. | CME Eligible
- 6:50 p.m.
Ann-Kathrin Eisfeld, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio - 7:20 p.m.
Sascha Dietrich, University of Düsseldorf, Düsseldorf, Germany - 7:50 p.m.
R. Coleman Lindsley, Dana-Farber Cancer Institute, Boston, Massachusetts
Opening Reception
8:30-10 p.m.
Continental Breakfast
7-8 a.m.
Plenary Session 2: Functional and Genomic Precision Medicine in Solid Tumors
8-9:35 a.m. | CME Eligible
- 8:05 a.m.
Benjamin D. Hopkins, Cornell University, New York, New York - 8:35 a.m.
Jesse S. Boehm, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
Additional speaker to be announced
Break
9:35-9:50 a.m.
Plenary Session 3: Ex vivo patient-derived Models to Identify Biomarkers of Response
9:50-11:25 a.m. | CME Eligible
- 9:55 a.m.
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York - 10:25 a.m.
Alice Soragni, University of California, Los Angeles, California - 10:55 a.m.
Chris Jones, The Institute of Cancer Research, Sutton, England
Break
11:25-11:40 a.m.
Panel Discussion 1: Regulatory and Non-Regulatory Challenges to the Wide Adoption of Precision Diagnostics
11:40 a.m.-12:40 p.m. | CME Eligible
Lunch on own/ Break
12:40-2:15 p.m.
Plenary Session 4: Vertebrate Models for Modeling Disease and Guiding Therapy
2:15-3:50 p.m. | CME Eligible
- 2:20 p.m.
Genevieve C. Kendall, The Ohio State University, Nationwide Children’s Hospital, Columbus, Ohio - 2:50-3:10 p.m.
Alvaro Curiel-Garcia, Columbia University Irving Medical Center, New York, New York - 3:20-3:40 p.m.
Peter J. Houghton, UT Health Science Center at San Antonio, San Antonio, Texas
Break
3:50-4 p.m.
Plenary Session 5: Challenges of Intra-Tumor and Intra-Patient Heterogeneity for Precision Medicine
4-5:35 p.m. | CME Eligible
Session Chair: Elaine R. Mardis, The Institute for Genomic Medicine at Nationwide Children’s Hospital, Columbus, Ohio
- 4:05 p.m.
Paul C. Boutros, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California - 4:35 p.m.
Elaine R. Mardis, The Institute for Genomic Medicine at Nationwide Children’s Hospital, Columbus, Ohio - 5:05 p.m.
Scott R. Manalis, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
Panel Discussion 2: Challenges in Tissue Acquisition and Handling for Precision Medicine
5:40-6:40 p.m. | CME Eligible
Poster Session / Reception
7-9 p.m.
Continental Breakfast
7-8 a.m.
Plenary Session 6: New Omics for Precision Medicine
8-9:35 a.m. | CME Eligible
- 8:05 a.m.
Bernhard Küster, Technical University of Munich, Freising, Germany - 8:35 a.m.
Thomas Kislinger, Princess Margaret Cancer Centre, Toronto, Ontario, Canada - 9:05 a.m.
M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania
Break
9:35-9:50 a.m.
Plenary Session 7: Machine Learning to Integrate Multiple Data Layers
- 9:55 a.m.
Taran Gujral, Fred Hutch Cancer Center, Seattle, Washington - 10:25 a.m.
Casey Greene, University of Colorado Anschutz Medical Campus, Aurora, Colorado - 10:55 a.m.
Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts
Break / Box Lunches Available
11:25 a.m.-12 p.m.
Plenary Session 8: Immunotherapy-predictive Biomarkers
12-1:35 p.m. | CME Eligible
- 12:05 p.m.
Patricia Perez-Galan, IDIBAPS Barcelona, Spain - 12:35 p.m..
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas - 1:05 p.m.
Anne Rios, Princess Maxima Center for Pediatric Oncology, CS Utrecht, The Netherlands
Break
1:35-1:50 p.m.
Plenary Session 9: Clinical Trial Design for Optimal Implementation of Precision Medicine
1:50-3:25 p.m. | CME Eligible
- 1:55 p.m.
Philipp Staber, Medical University of Vienna, Vienna, Austria - 2:25 p.m.
Candace M. Howard-Claudio, University of Mississippi Medical Center, Jackson, Mississippi - 2:55 p.m.
Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain
Closing Remarks
3:25 p.m.